Company Overview - Lexeo Therapeutics is a cardiac genetic medicines company focused on utilizing AAV gene therapy to address genetic cardiovascular diseases with high unmet needs [2] - The company's most advanced program targets Friedreich's ataxia, showing significant impacts on both cardiac and neurologic aspects of the disease [2] Treatment Efficacy - The gene therapy has resulted in all patients with abnormal heart mass returning to the normal range, indicating a positive effect on cardiac pathology [2] - Improvement in neurologic disease symptoms has been observed, with effect sizes on neurologic scales comparable to those of commercially approved therapies [2] Future Developments - Lexeo Therapeutics plans to move its Friedreich's ataxia program into a registrational study within the year, aiming to establish a new standard of care for this high unmet need disease [3]
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript